Table 2 |
|||
|
Rituximab maintenance versus retreatment: comparison of efficacy |
|||
|
Maintenance |
Retreatment |
P |
|
|
|
|||
|
Overall response rate (%) |
52% |
35% |
0.14 |
|
Complete response rate (%) |
27% |
4% |
0.007 |
|
% in continuous remission |
45% |
24% |
0.05 |
|
% remaining in continuous remission |
23% |
2% |
0.03 |
|
Median progression-free survival (months) |
31.7 |
7.4 |
0.007 |
|
Median duration of rituximab benefit (months) |
31.7 |
27.4 |
0.94 |
|
|
|||
|
Mohrbacher Arthritis Research & Therapy 2005 7(Suppl 3):S19 doi:10.1186/ar1739 |
|||